Profile
| Metric | Value |
|---|---|
| Full Name | Cytokinetics, Incorporated |
| Ticker | NASDAQ: CYTK |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | cytokinetics.com |
| Employees | 498 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $65.42 | |
| Price, 1D Change | +1.27% | |
| Market Cap | $8B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.60 | |
| Revenue | $18M | |
| Revenue, 1Y Change | +145.34% | |
| EPS | -$5.26 | |
| EPS, 1Y Change | +3.44% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:6 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$5.26 | |
| EPS Estimate | -$6.09 | |
| EPS Est. Change | -15.68% | |
| Revenue | $18.47M | |
| Revenue Estimate | $80.63M | |
| Revenue Est. Change | +336.46% | |
| Current Price | $65.42 | |
| Price Target | - | $84.00 |
| Price Tgt. Change | - | +28.40% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$4.97 | -$5.45 | -9.70% | |
| -$5.16 | -$5.26 | -1.98% | |
| -$6.09 | N/A | -15.68% | |
| -$5.86 | N/A | -11.39% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $19.05M | $7.53M | -60.47% | |
| $14.37M | $18.47M | +28.55% | |
| $80.63M | N/A | +336.46% | |
| $141.24M | N/A | +664.54% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +34.86% | |
| Price, 3Y | +51.61% | |
| Market Cap, 1Y | +39.49% | |
| Market Cap, 3Y | +95.46% | |
| Revenue, 1Y | +145.34% | |
| Revenue, 3Y | -73.77% | |
| EPS, 1Y | +3.44% | |
| EPS, 3Y | -87.99% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $65.42 | |
| SMA 200 | $46.44 | |
| SMA 200 vs Price | -29.01% | |
| SMA 50 | $63.50 | |
| SMA 50 vs Price | -2.93% | |
| Beta | 0.60 | |
| ATR | $2.81 | |
| 14-Day RSI | 56.00 | |
| 10-Day Volatility | 45.74% | |
| 1-Year Volatility | 65.36% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $18.47M | |
| EPS | -$5.26 | |
| Gross Profit | $8.94M | |
| Gross Margin | 48.41% | |
| Operating Profit | -$536.25M | |
| Operating Margin | -2,902.72% | |
| Net Income | -$589.53M | |
| Net Margin | -3,191.11% | |
| EBITDA | -$493.48M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -5.83 | |
| Current Ratio | 6.17 | |
| Quick Ratio | 6.17 | |
| - | ||
| F-Score | 3 | |
| Altman Z-Score | 0.05 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 91.72 | |
| PB Ratio | -15.35 | |
| EV/EBITDA | -14.61 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$135.37M | |
| Cash & Equivalents | $1.08B | |
| Total Assets | $1.40B | |
| Current Assets | $1.11B | |
| Total Liabilities | $1.54B | |
| Current Liabilities | $179.67M | |
| Total Debt | $788.68M | |
| Short Term Debt | $30.50M | |
| Accounts Payable | $20.37M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $554.72M | |
| Operating Expenses | $215.31M | |
| Cost Of Goods Sold | $9.53M | |
| SG&A | $215.31M | |
| D&A | $9.53M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$395.89M | |
| CFI | -$553.10M | |
| CFF | $930.61M | |
| Capex | $3.91M | |
| Free Cash Flow | -$399.80M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| RBC Capital | → | |
| Needham | → | |
| HC Wainwright & Co. | → | |
| Citizens | → | |
| Barclays | → | |
| Goldman Sachs | → | |
| Needham | → | |
| RBC Capital | → | |
| B. Riley Securities | → |
Analyst sentiment
Institutional ownership
Screeners with CYTK
Data Sources & References
- CYTK Official Website www.cytokinetics.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1061983/000119312525267059/0001193125-25-267059-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1061983/000095017025029206/0000950170-25-029206-index.htm
- CYTK Profile on Yahoo Finance finance.yahoo.com/quote/CYTK
- CYTK Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/cytk
FAQ
What is the ticker symbol for Cytokinetics, Incorporated?
The ticker symbol for Cytokinetics, Incorporated is NASDAQ:CYTK
Does Cytokinetics, Incorporated pay dividends?
No, Cytokinetics, Incorporated does not pay dividends
What sector is Cytokinetics, Incorporated in?
Cytokinetics, Incorporated is in the Healthcare sector
What industry is Cytokinetics, Incorporated in?
Cytokinetics, Incorporated is in the Biotechnology industry
What country is Cytokinetics, Incorporated based in?
Cytokinetics, Incorporated is headquartered in United States
When did Cytokinetics, Incorporated go public?
Cytokinetics, Incorporated initial public offering (IPO) was on April 30, 2004
Is Cytokinetics, Incorporated in the S&P 500?
No, Cytokinetics, Incorporated is not included in the S&P 500 index
Is Cytokinetics, Incorporated in the NASDAQ 100?
No, Cytokinetics, Incorporated is not included in the NASDAQ 100 index
Is Cytokinetics, Incorporated in the Dow Jones?
No, Cytokinetics, Incorporated is not included in the Dow Jones index
When was Cytokinetics, Incorporated last earnings report?
Cytokinetics, Incorporated's most recent earnings report was on November 5, 2025
When does Cytokinetics, Incorporated report earnings?
The next expected earnings date for Cytokinetics, Incorporated is February 26, 2026